These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 33188886)

  • 1. Dual Vasopressin Receptor Antagonism to Improve Congestion in Patients With Acute Heart Failure: Design of the AVANTI Trial.
    Goldsmith SR; Burkhoff D; Gustafsson F; Voors A; Zannad F; Kolkhof P; Staedtler G; Colorado P; Dinh W; Udelson JE
    J Card Fail; 2021 Feb; 27(2):233-241. PubMed ID: 33188886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vasopressin antagonism in heart failure: a review of the hemodynamic studies and major clinical trials.
    Urbach J; Goldsmith SR
    Ther Adv Cardiovasc Dis; 2021; 15():1753944720977741. PubMed ID: 33435837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Arginine vasopressin antagonism in heart failure: Current status and possible new directions.
    Goldsmith SR
    J Cardiol; 2019 Jul; 74(1):49-52. PubMed ID: 30904236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual Vasopressin V1a/V2 Antagonism: The Next Step in Neurohormonal Modulation in Patients With Heart Failure?
    Goldsmith SR; Udelson JE; Gheorghiade M
    J Card Fail; 2018 Feb; 24(2):112-114. PubMed ID: 29329950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac output improvement by pecavaptan: a novel dual-acting vasopressin V1a/V2 receptor antagonist in experimental heart failure.
    Mondritzki T; Mai TA; Vogel J; Pook E; Wasnaire P; Schmeck C; Hüser J; Dinh W; Truebel H; Kolkhof P
    Eur J Heart Fail; 2021 May; 23(5):743-750. PubMed ID: 32946151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach to treatment of acute heart failure.
    Goldsmith SR
    J Cardiol; 2016 May; 67(5):395-8. PubMed ID: 26946929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-Hospital Diuretic Agent Use and Post-Discharge Clinical Outcomes in Patients Hospitalized for Worsening Heart Failure: Insights From the EVEREST Trial.
    Mecklai A; Subačius H; Konstam MA; Gheorghiade M; Butler J; Ambrosy AP; Katz SD
    JACC Heart Fail; 2016 Jul; 4(7):580-588. PubMed ID: 27039131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.
    Gheorghiade M; Konstam MA; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1332-43. PubMed ID: 17384438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vasopressin receptor antagonists in heart failure.
    Hobbs RE; Tang WH
    Recent Pat Cardiovasc Drug Discov; 2006 Jun; 1(2):177-84. PubMed ID: 18232127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination decongestion therapy in hospitalized heart failure: loop diuretics, mineralocorticoid receptor antagonists and vasopressin antagonists.
    Vaduganathan M; Mentz RJ; Greene SJ; Senni M; Sato N; Nodari S; Butler J; Gheorghiade M
    Expert Rev Cardiovasc Ther; 2015; 13(7):799-809. PubMed ID: 26106934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.
    Konstam MA; Gheorghiade M; Burnett JC; Grinfeld L; Maggioni AP; Swedberg K; Udelson JE; Zannad F; Cook T; Ouyang J; Zimmer C; Orlandi C;
    JAMA; 2007 Mar; 297(12):1319-31. PubMed ID: 17384437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal effects of conivaptan, furosemide, and the combination in patients with chronic heart failure.
    Goldsmith SR; Gilbertson DT; Mackedanz SA; Swan SK
    J Card Fail; 2011 Dec; 17(12):982-9. PubMed ID: 22123359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tolvaptan in Patients Hospitalized With Acute Heart Failure: Rationale and Design of the TACTICS and the SECRET of CHF Trials.
    Felker GM; Mentz RJ; Adams KF; Cole RT; Egnaczyk GF; Patel CB; Fiuzat M; Gregory D; Wedge P; O'Connor CM; Udelson JE; Konstam MA
    Circ Heart Fail; 2015 Sep; 8(5):997-1005. PubMed ID: 26374918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.
    Kolkhof P; Pook E; Pavkovic M; Kretschmer A; Buchmüller A; Tinel H; Delbeck M; Mondritzki T; Wasnaire P; Dinh W; Truebel H; Hüser J; Schmeck C
    J Cardiovasc Pharmacol; 2019 Jul; 74(1):44-52. PubMed ID: 31274842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vasopressin and Vasopressin Antagonists in Heart Failure.
    Vishram-Nielsen JK; Gustafsson F
    Handb Exp Pharmacol; 2017; 243():307-328. PubMed ID: 28432473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure.
    Felker GM; Mentz RJ; Cole RT; Adams KF; Egnaczyk GF; Fiuzat M; Patel CB; Echols M; Khouri MG; Tauras JM; Gupta D; Monds P; Roberts R; O'Connor CM
    J Am Coll Cardiol; 2017 Mar; 69(11):1399-1406. PubMed ID: 27654854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel strategies: challenge loop diuretics and sodium management in heart failure--part II.
    Di Pasquale P; Sarullo FM; Paterna S
    Congest Heart Fail; 2007; 13(3):170-6. PubMed ID: 17541312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurohormonal Imbalance: A Neglected Problem-And Potential Therapeutic Target-In Acute Heart Failure.
    Goldsmith SR; Bart BA; Pin A IL
    Curr Probl Cardiol; 2018 Jul; 43(7):294-304. PubMed ID: 29310997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.